TICKERNERD
Menu
PAHCPAHCHealthcare · Drug Manufacturers - Specialty & Generic

PAHC Stock Forecast: Phibro Animal Health Corp. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$37
−1.56% on the day

The 4 Wall Street analysts covering Phibro Animal Health Corp. hold a median 12-month price target of $43 — +17.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.5B
Ticker Nerd rank
91 / 100
Median analyst target
$43
Analysts covering
4
Revenue$396.7M+4.8% y/y
Operating income$48.2M
Net income$21.7M
Free cash flow$5.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.3%
1M
−4.3%
YTD
−1.2%
1Y
−2.0%
From 52W high
−38.2%
From 52W low
+29.1%
$28
$59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PAHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phibro Animal Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
94
Revisions
90
Growth
89
Volatility
88
Momentum
50
Issuance
48
Size
39
Accruals
21

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PAHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PAHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$40$50$60Jan 26Apr 26Jul 26Oct 26PAHCHigh $55Median $43Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
1 Buy2 Hold1 Sell
Low $35Median $43High $55

The green dot is the last close — the median target sits +17.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026CitigroupMaintainsNeutral$62 → $44
14 May 2026CitigroupMaintainsNeutral—
15 Apr 2026CitigroupInitiatesNeutral—
7 Nov 2025JP MorganMaintainsOverweight—
29 Aug 2025B of A SecuritiesMaintainsUnderperform—
7 July 2025JP MorganUpgradeOverweight—
25 June 2025Morgan StanleyMaintainsEqual-Weight—
8 May 2025Morgan StanleyMaintainsEqual-Weight—
10 Feb 2025BarclaysMaintainsUnderweight—
17 Dec 2024Morgan StanleyMaintainsEqual-Weight—
12 Nov 2024BarclaysMaintainsUnderweight—
10 Sept 2024JP MorganInitiatesNeutral—
30 Aug 2024B of A SecuritiesMaintainsUnderperform—
10 May 2024BarclaysMaintainsUnderweight—
9 Nov 2023Morgan StanleyMaintainsEqual-Weight—
1 Sept 2023Roth MKMReiteratesBuy—
31 Aug 2023Morgan StanleyMaintainsEqual-Weight—
29 Aug 2023Roth MKMReiteratesBuy—
27 July 2023Morgan StanleyReiteratesEqual-Weight—
4 May 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PAHC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PAHC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Phibro Animal Health Corp. returned −2.0% against +17.3% for the S&P 500, dividends included.

PAHC vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26PAHCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PAHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.7%
Analysts raising
5
Analysts cutting
0
Fundamentals

Phibro Animal Health Corp. (PAHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.1×

Cheaper than 45% of US stocks

Price / sales
1.0×

Cheaper than 69% of US stocks

Price / book
3.9×

Cheaper than 25% of US stocks

EV / EBITDA
9.1×

Cheaper than 41% of US stocks

Growth & margins
Revenue growth (YoY)
4.8%

Higher than 38% of US stocks

Earnings growth (YoY)
26.0%

Higher than 63% of US stocks

Gross margin
33.9%

Higher than 40% of US stocks

Operating margin
10.6%

Higher than 65% of US stocks

Net margin
6.6%

Higher than 63% of US stocks

Returns & dividend
Return on equity
29.7%

Higher than 87% of US stocks

Return on assets
8.5%

Higher than 89% of US stocks

Dividend yield
1.3%

Higher than 73% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Phibro Animal Health Corp. (PAHC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Phibro Animal Health Corp. has a market value of $1.5B and an enterprise value of $2.2B.

  • Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 4.8% year on year.

  • Net income over the same four quarters: $99.7M, a 6.6% net margin.

  • Diluted earnings per share, trailing twelve months: $2.44.

  • Free cash flow in the twelve months to 30 June 2026: $9.9M, after $59.1M of capital spending.

  • Phibro Animal Health Corp. spent $19.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 40.6M.

  • Trailing P/E: 15.1×; forward P/E: 9.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.31%, paying out 20% of earnings.

  • Phibro Animal Health Corp. employs 2,605 people — $583K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

PAHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PAHCPhibro Animal Health Corp.$1.5B
91
ETONEton Pharmaceuticals, Inc.$1.6B
99
ANIPANI Pharmaceuticals, Inc.$1.6B
93
XERSXeris Biopharma Holdings, Inc.$1.8B
83
AMPHAmphastar Pharmaceuticals, Inc.$1.1B
86
PRGOPerrigo Co. Plc$1.9B
77
HROWHarrow, Inc.$1.1B
46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phibro Animal Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PAHC news & analysis

PAHC vs. HAE: Which Stock Is the Better Value Option?

Zacks Investment Research · 5 Oct 2026neutral

A Zacks Investment Research article compares Phibro Animal Health (PAHC) with Haemonetics (HAE) as potential value options within the Medical - Products sector, raising the question of which presents the better value opportunity. The piece evaluates both stocks from a value-investing perspective.

Why it matters — A PAHC watcher would care because the comparison offers a value-focused evaluation of the company relative to a sector peer, providing context on how analysts perceive its investment appeal.

Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report?

Zacks Investment Research · 25 Sept 2026negative

Phibro Animal Health Corp. (PAHC) reported earnings 30 days ago, and its stock has since declined 6.7%. The report examines what may be next for the company following the earnings release.

Why it matters — PAHC watchers would care because the stock has fallen notably since the earnings report, prompting questions about the company's near-term outlook.

Best Momentum Stocks to Buy for September 21st

Zacks Investment Research · 21 Sept 2026positive

Zacks Investment Research included Phibro Animal Health Corp. (PAHC) on its Zacks Rank #1 (Strong Buy) momentum stocks list dated September 21st, 2026, alongside SEI and SDRL.

Why it matters — A PAHC watcher would care because the company was highlighted on a notable momentum stock ranking, signalling recognition of its recent performance.

PAHC vs. HAE: Which Stock Should Value Investors Buy Now?

Zacks Investment Research · 18 Sept 2026neutral

Zacks Investment Research published a comparison of Phibro Animal Health (PAHC) and Haemonetics (HAE) as potential value opportunities for investors in the Medical - Products sector. The article poses the question of which of the two stocks offers the better value right now.

Why it matters — The piece highlights PAHC as a stock in the medical-products sector being evaluated against a peer for value-investing appeal, which could draw attention to the company.

Phibro Animal Health (PAHC) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · 17 Sept 2026positive

Zacks Investment Research reports that Phibro Animal Health (PAHC) has been identified as a top-ranked value stock based on its Style Scores system, which helps investors find top-rated stocks by investing style.

Why it matters — PAHC watchers would care because the stock has been highlighted by a prominent research firm as a top-ranked value stock, signaling favorable attention from the analysis community.

FAQ

Frequently asked questions about PAHC stock

What is the PAHC stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Phibro Animal Health Corp. have a median 12-month price target of $43, with estimates ranging from $35 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PAHC stock a buy right now?

Of the 4 analysts covering Phibro Animal Health Corp., 1 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Phibro Animal Health Corp. 91 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PAHC?

As at 6 Oct 2026, Phibro Animal Health Corp. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will PAHC stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +17.5% from the last close, and Ticker Nerd's factor model ranks Phibro Animal Health Corp. 91 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PAHC stock forecast for 2030?

No analyst covering Phibro Animal Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $55 over the next 12 months.

How has PAHC stock performed over the past year?

Phibro Animal Health Corp. returned -2.0% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phibro Animal Health Corp. do?

Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets.

What is the latest news on PAHC?

The most recent item we track (Zacks Investment Research, 5 Oct 2026): "PAHC vs. HAE: Which Stock Is the Better Value Option?". A Zacks Investment Research article compares Phibro Animal Health (PAHC) with Haemonetics (HAE) as potential value options within the Medical - Products sector, raising the question of which presents the better value opportunity. The piece evaluates both stocks from a value-investing perspective.

Company

About Phibro Animal Health Corp.

Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets. Its portfolio spans animal health solutions, mineral nutrition products, and performance products used in livestock production and animal care. The company serves customers across the agricultural and veterinary supply chains, where its offerings help address nutrition, health, and productivity needs in animal operations. Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey, and its Class A common stock is one of the company’s primary publicly traded equity classes.

CEO Mr. Daniel M. Bendheim J.D. · 2,605 employees · United States · https://www.pahc.com